The Journal of Heart and Lung Transplantation
Volume 27, Issue 4 , Pages 442-449 , April 2008

Decreased Myocardial Chromogranin A Expression and Colocalization With Brain Natriuretic Peptide During Reverse Cardiac Remodeling After Ventricular Unloading

  • Jeremias Wohlschlaeger, MD

      Affiliations

    • Department of Pathology and Neuropathology University Hospital Essen, University of Duisburg-Essen, Germany
    • ,
  • Moritz von Winterfeld

      Affiliations

    • Department of Pathology and Neuropathology University Hospital Essen, University of Duisburg-Essen, Germany
    • ,
  • Hendrik Milting, PhD

      Affiliations

    • Herz- und Diabeteszentrum NRW, Klinik für Thorax- und Kardiovaskularchirurgie, Erich und Hanna Klessmann-Institut für Kardiovaskuläre Forschung und Entwicklung, Bad Oeynhausen, Germany
    • ,
  • Aly El Banayosy, MD

      Affiliations

    • Herz- und Diabeteszentrum NRW, Klinik für Thorax- und Kardiovaskularchirurgie, Erich und Hanna Klessmann-Institut für Kardiovaskuläre Forschung und Entwicklung, Bad Oeynhausen, Germany
    • ,
  • Klaus Jürgen Schmitz, MD

      Affiliations

    • Department of Pathology and Neuropathology University Hospital Essen, University of Duisburg-Essen, Germany
    • ,
  • Atsushi Takeda, MD

      Affiliations

    • Faculty of Health Science, School of Physical Therapy, Gumma Paz College, Gumma, Japan
    • ,
  • Nobuakira Takeda, MD

      Affiliations

    • Department of Internal Medicine, Jikei University, Tokyo, Japan
    • ,
  • Petra Azhari, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, University Hospital Essen, Germany
    • ,
  • Christof Schmid, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, University of Regensburg, Germany
    • ,
  • Christian August, MD

      Affiliations

    • Department of Pathology, University Hospital Münster, Germany.
    • ,
  • Kurt Werner Schmid, MD

      Affiliations

    • Department of Pathology and Neuropathology University Hospital Essen, University of Duisburg-Essen, Germany
    • ,
  • Hideo Andreas Baba, MD

      Affiliations

    • Department of Pathology and Neuropathology University Hospital Essen, University of Duisburg-Essen, Germany
    • Corresponding Author InformationReprint requests: Univ.-Prof. Dr. med. H. A. Baba, Institute of Pathology and Neuropathology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany. Telephone: 0049-201-723-3577. Fax: 0049-201-723-3378.

Received 4 October 2007 ,Revised 10 January 2008 ,Accepted 12 January 2008.

References 

  1. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 1982;49:1659–1666
  2. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients (Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion). J Clin Invest. 1986;78:1362–1374
  3. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994;89:1573–1579
  4. Blaschko H, Comline RS, Schneider FH, Silver M, Smith AD. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature. 1967;215:58–59
  5. Pernow J, Lundberg JM, Kaijser L, et al. Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clin Physiol. 1986;6:561–578
  6. O’Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med. 1984;311:764–770
  7. Ceconi C, Ferrari R, Bachetti T, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J. 2002;23:967–974
  8. Metz-Boutigue MH, Garcia-Sablone P, Hogue-Angeletti R, Aunis D. Intracellular and extracellular processing of chromogranin A (Determination of cleavage sites). Eur J Biochem. 1993;217:247–257
  9. Curry WJ, Johnston CF, Hutton JC, et al. The tissue distribution of rat chromogranin A-derived peptides: evidence for differential tissue processing from sequence specific antisera. Histochemistry. 1991;96:531–538
  10. Mahata SK, O’Connor DT, Mahata M, et al. Novel autocrine feedback control of catecholamine release (A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist). J Clin Invest. 1997;100:1623–1633
  11. Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept. 1992;41:9–18
  12. Corti A, Mannarino C, Mazza R, Colombo B, Longhi R, Tota B. Vasostatins exert negative inotropism in the working heart of the frog. Ann N Y Acad Sci. 2002;971:362–365
  13. Imbrogno S, Angelone T, Corti A, Adamo C, Helle KB, Tota B. Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action. Gen Comp Endocrinol. 2004;139:20–28
  14. Pieroni M, Corti A, Tota B, et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J. 2007;28:1117–1127
  15. Gattenlohner S, Waller C, Ertl G, Bultmann BD, Muller-Hermelink HK, Marx A. NCAM(CD56) and RUNX1(AML1) are up-regulated in human ischemic cardiomyopathy and a rat model of chronic cardiac ischemia. Am J Pathol. 2003;163:1081–1090
  16. Bertrand AT, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. van E, V Cardiovasc Res. 2005;67:21–29
  17. Kuhn M, Voss M, Mitko D, et al. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage sheart failure. Cardiovasc Res. 2004;64:308–314
  18. Baba HA, Grabellus F, August C, et al. Reversal of metallothionein expression is different throughout the human myocardium after prolonged left-ventricular mechanical support. J Heart Lung Transplant. 2000;19:668–674
  19. Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation. 1998;98:656–662
  20. Milting H, Kassner A, et al. The time course of natriuretic hormones as plasma markers of myocardial recovery in heart transplant candidates during ventricular assist device support reveals differences among device types. EL BA J Heart Lung Transplant. 2001;20:949–955
  21. Bruggink AH, van Oosterhout MF, et al. Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device. de JN J Heart Lung Transplant. 2006;25:174–180

 This study was supported by the Deutsche Forschungsgemeinschaft (DFG) to H. A. Baba (Ba 1730/9–1) and to C. Schmid (Va 156/5–2).

PII: S1053-2498(08)00045-4

doi: 10.1016/j.healun.2008.01.017

The Journal of Heart and Lung Transplantation
Volume 27, Issue 4 , Pages 442-449 , April 2008

Article Tools

* Image Usage & Resolution